Authors:
Address: Unité de parasitologie, Unité de recherche sur les maladies infectieuses et transmissibles émergentes - UMR 6236, Institut de recherche biomédicale des armées - antenne de Marseille, Allée du Médecin-colonel Jamot, Parc le Pharo, BP 60109, 13262 Marseille Cedex 7, France.
Journal:

Publication:
Free Text: Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.

abstract

BACKGROUND:

One of the major complications of Plasmodium falciparum infection is cerebral malaria (CM), which causes one million deaths worldwide each year, results in long-term neurological sequelae and the treatment for which is only partially effective. Statins are recognized to have an immunomodulatory action, attenuate sepsis and have a neuroprotective effect. Atorvastatin (AVA) has shown in vitro anti-malarial activity and has improved the activity of mefloquine (MQ) and quinine.

METHODS:

The efficiency of 40 mg/kg intraperitoneal AVA, alone or in association with MQ, was assessed in an experimental Plasmodium berghei ANKA rodent parasite model of CM and performed according to different therapeutic schemes. The effects on experimental CM were assessed through the evaluation of brain histopathological changes and neuronal apoptosis by TUNEL staining.

RESULTS:

AVA alone in the therapeutic scheme show no effect on survival, but the prophylactic scheme employing AVA associated with MQ, rather than MQ alone, led to a significant delay in mouse death and had an effect on the onset of CM symptoms and on the level of parasitaemia. Histopathological findings show a correlation between brain lesions and CM onset. A neuronal anti-apoptotic effect of AVA in the AVA + MQ combination was not shown.

CONCLUSIONS:

The combination of AVA and MQ therapy led to a significant delay in mouse mortality. There were differences in the incidence, time to cerebral malaria and the level of parasitaemia when the drug combination was administered to mice. When used in combination with MQ, AVA had a relevant effect on the in vivo growth inhibition and clinical outcome of P. berghei ANKA-infected mice.

Related Articles
Impact of cerebral malaria on brain distribution of mefloquine.
Drug Metab Lett. 2009
Impact of cerebral malaria on brain distribution of mefloquine.
de Lagerie SB, Fernandez C, German-Fattal M, Gantier JC, Gimenez F, Farinotti R. Drug Metab Lett. 2009 Jan; 3(1):15-7.
Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.
Malar J. 2010
Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.
Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, Gil M, Baret E, Amalvict R, Rogier C, Pradines B. Malar J. 2010 May 25; 9:139. Epub 2010 May 25.
Recombinant human erythropoietin increases survival and reduces neuronal apoptosis in a murine model of cerebral malaria.
Malar J. 2008
Recombinant human erythropoietin increases survival and reduces neuronal apoptosis in a murine model of cerebral malaria.
Wiese L, Hempel C, Penkowa M, Kirkby N, Kurtzhals JA. Malar J. 2008 Jan 7; 7:3. Epub 2008 Jan 7.
Review Conventional and experimental treatment of cerebral malaria.
Int J Parasitol. 2006
Review Conventional and experimental treatment of cerebral malaria.
Golenser J, McQuillan J, Hee L, Mitchell AJ, Hunt NH. Int J Parasitol. 2006 May 1; 36(5):583-93. Epub 2006 Mar 13.
Review [Combined antimalarial therapy using artemisinin].
Parassitologia. 2004
Review [Combined antimalarial therapy using artemisinin].
Majori G. Parassitologia. 2004 Jun; 46(1-2):85-7.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster